Infinity Pharmaceuticals reports data from IPI-145 blood cancer studies Infinity Pharmaceuticals ( INFI ) reports preclinical data that demonstrates the activity of IPI-145 (PI3K inhibitor) in models of DLBCL and T-ALL. INFI also says Phase 1 data in aNHL shows the treatment "led to a reduction in adenopathy" in three of eight DLBCL patients and two of three with Richter transformation. ( PR ) in other company news from ASH, INFI says updated Phase 1 data from an ...
Dec. 8, 2013 - Seeking Alpha